SML3682

ST2825

≥98% (HPLC)

• 同義詞: (2R,4′R,8′aR)-1-[2-[4-[[2-(2,4-Dichlorophenoxy)acetyl]amino]phenyl]acetyl]tetrahydro-6′-oxo-spiro[pyrrolidine-2,7′(6′H)-[2H]pyrrolo[2,1-b][1,3]thiazine]-4′-carboxamide, PAM4-SP19-Beta8-NH2, ST 2825, ST-2825
• 經驗公式（希爾表示法）: C₂₇H₂₈Cl₂N₄O₅S
• CAS號碼: 894787-30-5
• 分子量：: 591.51
• MDL號碼: MFCD30207830
• 分類程式碼代碼: 51111800
• 分類程式碼代碼: 12352200
• NACRES: NA.21

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: white to beige
• 溶解度: DMSO: 2 mg/mL, clear
• 儲存溫度: -10 to -25°C

描述

生化／生理作用

Orally active peptidomimetic MyD88 homodimerization inhibitor with in vitro and in vivo efficacy against IL-1R and TLR9-dependent processes.

ST2825 is an orally active peptidomimetic of a heptapeptide structure in the MyD88 TIR BB-loop. ST2825 prevents IL-1beta-mediated activation of NF-kappaB by blocking MyD88 homodimerization and thereby the recruitment of IL-1 receptor-associated kinases IRAK1/4. ST2825 at 10 µg/mL completely suppresses 2.5 µg/mL TLR9 ligand ODN 2006-induced B-cell plasma cell differentation and antibodies production from PBMCs. ST2825 inhibits IL-1β-induced IL-6 production in mice (100 & 200 mg/kg p.o. prior to 20 µg/kg IL-1β i.p.) and protects against left ventricular (LV) dilatation and hypertrophy (25 mg/kg/day i.p.) in a murine model of nonreperfused acute myocardial infarction (AMI) in vivo.

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable